Recent healthcare and political changes are opening the door for medical device companies.
The union will strengthen BD’s leadership in medication management and infection prevention, and increase opportunities in fast-growing clinical areas and OUS markets.
An overview of the process, actionable strategies and tactics, key considerations, and mistakes to avoid, whether executing in-house or together with an outside expert.
Many companies go for product approval in smaller markets first. Is that the right decision?
The expanding international market poses a variety of challenges for medtech companies entering new global territories.
When entering this emerging market, the benefits may outweigh any risks.
The device tax, regulatory scrutiny, and a failure to address unmet clinical needs are among the reasons that the United States will fall behind other major markets.
In this interview Brian Williams, Director, Healthcare Strategy and Innovation at PwC, talks about the impact of med-tech trends such as outcomes based reimbursement, lessons learned in emerging markets, and impact of the device tax.
In order to compete globally, companies must be proactive in their business plans and anticipate the challenges they may face, concur three med-tech executives.